Compare OSCR & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSCR | CRSP |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 4.4B |
| IPO Year | 2021 | 2016 |
| Metric | OSCR | CRSP |
|---|---|---|
| Price | $11.49 | $47.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 17 |
| Target Price | $17.00 | ★ $70.29 |
| AVG Volume (30 Days) | ★ 5.8M | 1.9M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,701,427,000.00 | $289,590,000.00 |
| Revenue This Year | $63.73 | $1,082.59 |
| Revenue Next Year | $5.40 | $87.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 27.50 | ★ 9169.85 |
| 52 Week Low | $10.69 | $30.06 |
| 52 Week High | $23.80 | $78.48 |
| Indicator | OSCR | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 37.24 | 43.87 |
| Support Level | N/A | $45.53 |
| Resistance Level | $15.56 | $60.63 |
| Average True Range (ATR) | 0.63 | 1.95 |
| MACD | -0.18 | -0.27 |
| Stochastic Oscillator | 25.60 | 52.97 |
Oscar Health Inc is a healthcare technology company built around a full stack technology platform and a relentless focus on serving its members. It offers Individual & Family plans and health technology solutions that power the healthcare industry. Oscar operates as one segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act (ACA) and leverages its technology platform to provide services via its Oscar offering.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.